| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $8.7M | +11.4% | -48.2% |
| SG&A Expense | $1.9M | -2.0% | +0.6% |
| Operating Income | -$10.6M | -8.7% | +43.3% |
| Net Income | -$9.7M | -9.8% | +44.5% |
| EPS (Basic) | -$0.10 | -11.1% | +54.5% |
| EPS (Diluted) | -$0.10 | -11.1% | +54.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $76.9M | -7.9% | -9.3% |
| Current Assets | $79.1M | -9.1% | -8.1% |
| Total Assets | $79.2M | -9.1% | -8.2% |
| Current Liabilities | $6.0M | +32.5% | +158.8% |
| Total Liabilities | $6.1M | +31.5% | +145.0% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$17.4M | — | — |
| Capital Expenditures | $34K | — | — |
| Investing Cash Flow | -$34K | — | — |
| Financing Cash Flow | -$15K | — | — |
| Free Cash Flow | -$17.5M | — | — |
| $73.2M |
| -11.4% |
| -12.7% |